Effect of cyclosporin a on the allergen-induced late asthmatic reaction

Thorax

Volumn 52, Issue 5, 1997, Pages 447-452

  Sihra, Bhupinder S ^a   Kon, Onn M ^a   Durham, Stephen R ^a   Walker, Samantha ^a   Barnes, Neil C ^b   Kay, A Barry ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

Cosinophils; Cyclosporin A; Late asthmatic reactions

Indexed keywords

CYCLOSPORIN A;

ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGRANULATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EXOCYTOSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

EID: 0031008530     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.5.447     Document Type: Article

References (45)

1. Durham SR. Late asthmatic responses. Respir Med 1990; 84:263-8.
2. Casale TB, Wood D, Richerson HB, Zchr B, Zavala D, Hunninghake GW. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J Clin Invest 1987;80:1507 11.
3. Liu MC, Hubbard WC, Proud D, Stealey BA, Galli SJ, Kagey-Sobotka A, et al. Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes. Am Rev Respir Dis 1991:144:51-8.
4. Metzger WJ, Zavala D, Richerson HB, Moseley P, Iwamoto P, Monick M, et al. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs: description of the model and local airway inflammation. Am Rev Respir Dis 1987;135:433-40.
5. Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils and cytokine mRNA expression for interleukin-5 and granulocyte macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. Am J Respir Cell Mol Biol 1993;8:35 42.
6. H2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993;92:313-24.
7. Virchow JC, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, et al. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995;151:960-8.
8. Dahl R, Venge P, Olsson I. Variations of blood eosinophils and eosinophil cationic protein in serum in patients with bronchial asthma: studies during inhalation challenge test. Allergy 1978;33:211 5.
9. Durham SR, Loegering DA, Dunnette S, Gleich GJ, Kay AB. Blood eosinophils and eosinophil-derived proteins in allergic asthma. J Allergy Clin Immunol 1989;84:931-6.
10. Wardlaw AJ, Moqbel R, Kay AB. Eosinophils: biology and role in disease. Adv Immunol 1995;60:151-266.
11. Laitinen LA, Laitinen A, Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis 1993;147:697-704.
12. Cockcroft DW, Murdock KY. Comparative effects of inhaled salbutamol, sodium cromoglycate, and beclomethasone diproprionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79:734-40.
13. Brynskov J, Freund L, Rasmussen SN, Lauritsen K, Shaffalitzky de Muckadell O, Williams N, et al. A placebocontrolled, double-blind, randomised trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989;321:845-50.
14. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991;324:277 84.
15. Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, et al. Low dose cyclosporin in patients with rheumatoid arthritis, Lancet 1990;335:1051 4.
16. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, cross-over study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
17. Azzawi M, Bradley B, Jeffery PK, Frew A, Wardlaw AJ, Knowles G, et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990;142:1407-13.
18. Corrigan CJ, Kay AB. CD4 T-lymphocyte activation in acute severe asthma: relationship to disease severity and atopic status. Am Rev Respir Dis 1990;141:970 7.
19. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991;88:935-42.
20. H2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298 304.
21. H2-type (interleukin 2 and interferon g) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal subjects. Am J Respir Cell Mol Biol 1995;12:477 87.
22. Alexander AG, Barnes NC, Kay AB. Trial of cyclosporin in corticosteroid-dependent chronic severe asthma. Lancet 1992;339:324-8.
23. Lock SH, Kay AB, Barnes NC. Double-blind, placebocontrolled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Raspir Crit Care Med 1996;153:509-14.
24. Mori A, Suko M, Nishizaki Y, Kobayashi S, Matsuzaki G, Yamamoto K, et al. IL-5 production by CD4 + T cells of asthmatic patients is suppressed by glucocorticoids and the immunosuppressants FK506 and cyclosporin A. Int Immunol 1995;7:449-57.
25. Sano T, Nakamura Y, Matsunanga Y, Takahashi T, Azuma M, Okano Y, et al. FK506 and cyclosporin A inhibit granulocyte-macrophage colony-stimulating factor production by mononuclear cells in asthma, Eur Respir J 1995;8:1473-8.
26. 2 release from human lung mast cells by ciclosporin A. Int Arch Allergy Appl Immunol 1989;88:253-5.
27. Casolaro C, Spadaro G, Patella V, Marone G. In vivo characterisation of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 1993;151:5563-73.
28. Pocock SJ. Cross-over trials. In: Pocock SJ, ed. Clinical trials: a practical approach. Chichester: John Wiley, 1983: 116-7.
29. Ohnishi T, Kita H, Weiler D, Sur S, Sedgwick JB, Calhoun WJ, et al. IL-5 is the predominant eosinophil-active cylokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993;147:901 7.
30. Woolkey KL, Adelroth M, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, cosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Came Med 1995;151:1915 24.
31. Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ. Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995;182:1169 74.
32. Bradding P. Human mast cell cytokines. Clin Exp Allergy 1996;26:13 9.
33. Moqbel R, Levi-Schaffer F, Kay AB. Cytokine generation by eosinophils. J Allergy Clin Immunol 1994;94:1183-8.
34. Vancheri C, Gauldie J, Bienenstock J, Cox G, Scicchitano R, Stanisz A, et al. Human lung fibroblast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) mediates eosinophil survival in vitro. Am J Respir Cell Mol Biol 1989;1:289-95.
35. Her E, Frazer J, Austen KF, Owen WF. Eosinophil haematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell conditioned medium. J Clin Invest 1991;88:1982-7.
36. Abdelaziz MM, Devalia JL, Khair OA, Calderon M, Sapsford RJ, Davies RJ. The effect of conditioned medium from cultured human bronchial epithelial cells on eosinophil and neutrophil chemotaxis and adherence in vitro. Am J Respir Cell Mol Boil 1995;13:728-37.
37. Cookson WOCM, Craddock CF, Benson MK, Durham SR. Falls in peripheral eosinophil counts parallel the late asthmatic response. Am Rev Respir Dis 1989;139:458 62.
38. Aalbers R, de Monchy JGR, Kauffman HF, Smith M, Hoekstra Y, Vrugt B, et al. Dynamics of eosinophil infiltration in the bronchial mucosa before and after the late asthmatic reaction. Eur Raspir J 1993;6:840 7.
39. Rossi GA, Crimi E, Lantero S, Gianiorio P, Oddera S, Crimi P, et al. Late-phase asthmatic reaction to inhaled allergen is associated with early recruitment of eosinophils in the airways. Am Res Respir Dis 1991;144:379 83.
40. Siekerka JJ, Sigal NH. FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol 1992;4:548-52.
41. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte macrophage colony-stimulating factor and interleukin-3 release from peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745 8.
42. Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell cytokine production. J Pharm Exp Ther 1992;260:680 8.
43. Bonham CA, Thomson AW. Immunosuppressants (drugs and monoclonal antibodies). In: Kay AB, ed. Allergy and allergic diseases. Oxford: Blackwell Science, 1997 (in press).
44. Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production in vitro at a single cell level. Immunology 1992;75:136-42.
45. Arima M, Yukawa T, Terashi Y, Makino S. Effects of inhaled cyclosporin A on the allergen-induced late asthmatic response and increase in airway hyperresponsiveness in a guinea pig model of asthma. Japan J Allergol 1994;43: 1316-25.